Literature DB >> 23083497

FAZA PET/CT hypoxia imaging in patients with squamous cell carcinoma of the head and neck treated with radiotherapy: results from the DAHANCA 24 trial.

Lise Saksø Mortensen1, Jørgen Johansen, Jesper Kallehauge, Hanne Primdahl, Morten Busk, Pernille Lassen, Jan Alsner, Brita S Sørensen, Kasper Toustrup, Steen Jakobsen, Jørgen Petersen, Henrik Petersen, Jørn Theil, Marianne Nordsmark, Jens Overgaard.   

Abstract

PURPOSE: Hypoxia is a cause of resistance to radiotherapy, especially in patients with head and neck squamous cell carcinoma (HNSCC). The purpose of this study was to evaluate (18)F-fluoroazomycin arabinoside (FAZA) positron emission tomography (PET)/computed tomography (CT) hypoxia imaging as a prognostic factor in HNSCC patients receiving radiotherapy.
MATERIAL AND METHODS: Forty patients with HNSCC treated with radiotherapy (66-76 Gy) were included. Static FAZA PET/CT imaging 2h post injection was conducted prior to irradiation. The hypoxic volume (HV) was delineated using a tumor-to-muscle value ≥ 1.4. In 13 patients, a repetitive FAZA PET/CT scan was conducted during the radiotherapy treatment.
RESULTS: A hypoxic volume could be identified in 25 (63%) of the 40 tumors. FAZA PET HV varied considerably with a range from 0.0 to 30.9 (median: 0.3) cm(3). The T(max)/M(med) ranged from 1.1 to 2.9 (median: 1.5). The distribution of hypoxia among the Human Papillomavirus (HPV) positive (12/16) and negative (13/24) tumors was not significant different. In the FAZA PET/CT scans performed during radiotherapy, hypoxia could be detected in six of the 13 patients. For these six patients the location of HV remained stable in location during radiotherapy treatment, though the size of the HV decreased. In 30 patients a positive correlation was detected between maximum FAZA uptake in the primary tumor and the lymph node. During a median follow up of 19 months a significant difference in disease free survival rate with 93% for patients with non hypoxic tumors and 60% for patients with hypoxic tumors could be detected.
CONCLUSION: This study emphasizes the role of FAZA PET/CT imaging as a suitable assay with prognostic potential for detection of hypoxia in HNSCC.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23083497     DOI: 10.1016/j.radonc.2012.09.015

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  87 in total

1.  Dosimetry study of 18F-FMISO + PET/CT hypoxia imaging guidance on intensity-modulated radiation therapy for non-small cell lung cancer.

Authors:  H Li; D Xu; X Han; Q Ruan; X Zhang; Y Mi; M Dong; S Guo; Y Lin; B Wang; G Li
Journal:  Clin Transl Oncol       Date:  2018-04-05       Impact factor: 3.405

2.  Biological Features of Human Papillomavirus-related Head and Neck Cancers Contributing to Improved Response.

Authors:  C Cleary; J E Leeman; D S Higginson; N Katabi; E Sherman; L Morris; S McBride; N Lee; N Riaz
Journal:  Clin Oncol (R Coll Radiol)       Date:  2016-04-01       Impact factor: 4.126

Review 3.  PET imaging biomarkers in head and neck cancer.

Authors:  Sarah Differding; François-Xavier Hanin; Vincent Grégoire
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-01-09       Impact factor: 9.236

Review 4.  Biological imaging in clinical oncology: radiation therapy based on functional imaging.

Authors:  Yo-Liang Lai; Chun-Yi Wu; K S Clifford Chao
Journal:  Int J Clin Oncol       Date:  2016-07-06       Impact factor: 3.402

Review 5.  Positron emission tomography to assess hypoxia and perfusion in lung cancer.

Authors:  Eline E Verwer; Ronald Boellaard; Astrid Am van der Veldt
Journal:  World J Clin Oncol       Date:  2014-12-10

6.  Predictive value of hypoxia in advanced head and neck cancer after treatment with hyperfractionated radio-chemotherapy and hypoxia modification.

Authors:  B Clavo; F Robaina; D Fiuza; A Ruiz; M Lloret; D Rey-Baltar; P Llontop; A Riveros; J Rivero; F Castañeda; S Quintero; N Santana-Rodríguez
Journal:  Clin Transl Oncol       Date:  2016-08-15       Impact factor: 3.405

7.  Diffuse optical measurements of head and neck tumor hemodynamics for early prediction of chemoradiation therapy outcomes.

Authors:  Lixin Dong; Mahesh Kudrimoti; Daniel Irwin; Li Chen; Sameera Kumar; Yu Shang; Chong Huang; Ellis L Johnson; Scott D Stevens; Brent J Shelton; Guoqiang Yu
Journal:  J Biomed Opt       Date:  2016-08-01       Impact factor: 3.170

8.  Quantitative and qualitative analysis of [(18)F]FDG and [(18)F]FAZA positron emission tomography of head and neck cancers and associations with HPV status and treatment outcome.

Authors:  Edward E Graves; Rodney J Hicks; David Binns; Mathias Bressel; Quynh-Thu Le; Lester Peters; Richard J Young; Danny Rischin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-11-18       Impact factor: 9.236

9.  Lesion oxygenation associates with clinical outcomes in premalignant and early stage head and neck tumors treated on a phase 1 trial of photodynamic therapy.

Authors:  Peter H Ahn; Jarod C Finlay; Shannon M Gallagher-Colombo; Harry Quon; Bert W O'Malley; Gregory S Weinstein; Ara Chalian; Kelly Malloy; Thomas Sollecito; Martin Greenberg; Charles B Simone; Sally McNulty; Alexander Lin; Timothy C Zhu; Virginia Livolsi; Michael Feldman; Rosemarie Mick; Keith A Cengel; Theresa M Busch
Journal:  Photodiagnosis Photodyn Ther       Date:  2017-11-04       Impact factor: 3.631

10.  A prospective clinical study of ¹⁸F-FAZA PET-CT hypoxia imaging in head and neck squamous cell carcinoma before and during radiation therapy.

Authors:  Stéphanie Servagi-Vernat; Sarah Differding; Francois-Xavier Hanin; Daniel Labar; Anne Bol; John A Lee; Vincent Grégoire
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-02-26       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.